Related Experiment Videos
[Endomyocardial biopsy in cardiopathy of unknown origin]
Insights
Endomyocardial biopsy (EMB) aids in diagnosing heart conditions of uncertain origin (CPUO) when other methods fail. This safe procedure proved valuable in specific cases, identifying rare myocardial diseases.
Area of Science:
- Cardiology
- Pathology
Context:
- Diagnosing cardiopathy of uncertain origin (CPUO) presents challenges.
- Noninvasive methods may not always identify the specific cardiac disease.
Purpose:
- To evaluate the diagnostic value and safety of endomyocardial biopsy (EMB) in adult patients with CPUO.
Summary:
- Endomyocardial biopsy (EMB) was performed on 21 adult patients (18-59 years) with preliminary CPUO diagnosis.
- EMB provided substantial diagnostic value in 2 patients (myocardial hypereosinophilia, amyloidosis).
- Results were non-specific in 18 patients, and normal in 1 patient.
Impact:
- EMB is a useful and safe diagnostic tool for precisely defined patient groups.
- This procedure can identify specific myocardial pathologies not detectable by other means.
Abstract:
The authors described their experiences with endomyocardial biopsy (EMB) in 21 adult patients aged from 18 to 59 years with the preliminary diagnosis of cardiopathy of uncertain origin (CPUO). Their definition of CPUO is as symptoms and/or findings of cardiac disease, which cannot be exactly identify using even complex clinical and noninvasive cardiological diagnostic procedures. Diagnostic value of EMB was substantial in two of their patients (in one hypereosinophilia of myocardium, and in another amyloidosis), non specific results were found in 18 patients, and 1 patient had normal pattern of the biopsy. EMB is useful and safe clinical diagnostic procedure in exactly defined groups of patients.